Volume 104, Issue 3 , Pages 189-193, March 2009
Cost-effectiveness of misoprostol and prenatal iron supplementation as maternal mortality interventions in home births in rural India
Abstract
Objective
To determine the cost-effectiveness of prenatal iron supplementation and misoprostol use as interventions to prevent maternal mortality in home births in rural India.
Methods
A cost-effectiveness analysis depicted three hypothetical cohorts of 10
000 pregnant women delivering at home in rural India: one with no intervention, one receiving standard prenatal iron supplements, and 1 receiving 600 µg of misoprostol in the third stage of labor.
Results
Misoprostol used to prevent postpartum hemorrhage resulted in a 38% (95% CI, 5%–73%) decrease in maternal deaths, while prenatal iron supplementation resulted in a 5% (95% CI, 0%–47%) decrease. Misoprostol cost a median US $1401 (IQR US $1008–$1848) prenatal iron supplementation cost a median US $2241 (IQR No Lives Saved–$3882) per life saved compared with the standard care outcome.
Conclusion
Misoprostol is a cost-effective maternal mortality intervention for home births. Iron supplementation may be worthwhile to improve women's health, but it is uncertain whether it can prevent mortality after hemorrhage.
Keywords: Cost-effectiveness, Home birth, Iron supplementation, Maternal mortality, Misoprostol
To access this article, please choose from the options below
PII: S0020-7292(08)00459-1
doi:10.1016/j.ijgo.2008.10.011
© 2008 Elsevier Ireland Ltd. All rights reserved.
Volume 104, Issue 3 , Pages 189-193, March 2009
